TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02223754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B
Description: Soft contact lens to be worn as daily wear, monthly replacement modality.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Soft contact lens to be worn as daily wear, monthly replacement modality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Soft contact lens to be worn as daily wear, daily disposable modality.
Study: NCT02836236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF 25 mg tablet administered orally once daily
Study: NCT02223754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Soft contact lens to be worn as daily wear, daily disposable modality.
Study: NCT01177839

Intervention type: OTHER
Intervention: Screening sheets
Description: Reviewing screening sheets
Study: NCT02906202

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LentiGlobin BB305 Drug Product
Description: LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Study: NCT02169037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM Ablation
Description: Substrate ablation for AF, via ablation of rotors and focal sources alone.
Study: NCT02836236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: TDF 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: TAF placebo tablet administered orally once daily
Study: NCT02169037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional AF ablation with PVI
Description: Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
Study: NCT03930134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sparse uterine suture
Description: The slowly absorbed Vicryl 1 suture with a large round needle is introduced intramyometrially right above the endometrium. The suture starts in one corner and proceeds along the lower then the upper edge returning back to the incision point. Subserous layer is closed upon using the same thread in order to cover the purse suture and to complete the haemostasis while increasing the wound thickness.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: one layer uterine closure
Description: one layer classical continious uterine closure using slowly absorbed Vicryl 1
Study: NCT02836236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: TDF placebo tablet administered orally once daily
Study: NCT01608243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLIT tablets of house dust mite allergen extracts
Description: 10 dosing days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: 10 dosing days
Study: NCT04186806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray
Description: 20 ml bottle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray
Description: 20 ml bottle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray
Description: 44.3 ml bottle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray
Description: 44.3 ml bottle
Study: NCT04323306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMV688533
Description: Investigational medicinal product
Study: NCT03596281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Q3W IV
Study: NCT02285595

Intervention type: DEVICE
Group type: OTHER
Intervention: Sonendo GentleWave™ System
Study: NCT00210522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ 333369
Description: Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
Study: NCT01252121

Intervention type: OTHER
Group type: OTHER
Intervention: Systane Ultra Lubricant Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Systane Ultra Lubricant Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Systane Ultra Lubricant Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Systane Ultra Lubricant Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Systane Ultra Lubricant Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Systane Ultra Lubricant Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Hialid 0.1 Artificial Tears Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Hialid 0.1 Artificial Tears Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Hialid 0.1 Artificial Tears Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Hialid 0.1 Artificial Tears Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Hialid 0.1 Artificial Tears Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Hialid 0.1 Artificial Tears Eye Drops
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Unisol 4 Saline Solution
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Unisol 4 Saline Solution
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Unisol 4 Saline Solution
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Unisol 4 Saline Solution
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Unisol 4 Saline Solution
Description: One drop in study eye, one time, during office visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Unisol 4 Saline Solution
Description: One drop in study eye, one time, during office visit.
Study: NCT03933332

Intervention type: OTHER
Intervention: Diaphragm thickness
Description: measured at apposition zone using ultrasonography in mm

Intervention type: OTHER
Intervention: Cross-sectional area of rectus femoris muscle
Description: measured at lower one-third line between Spina iliaca anterior inferior (SIAI) and upper border femur patella using ultrasonography in cm\^2

Intervention type: OTHER
Intervention: Cross-sectional area of biceps brachii
Description: measured at biceps brachii muscle using ultrasonography in cm\^2

Intervention type: DIAGNOSTIC_TEST
Intervention: C-Reactive Protein (CRP) Level
Description: quantitative CRP using ELISA method in mcg/mL
Study: NCT04109742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphatidylcholine-curcumin complex supplement
Description: a dietary curcumin supplement given at two different doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphatidylcholine-curcumin complex supplement
Description: a dietary curcumin supplement given at two different doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo curcumin capsule
Description: matching placebo to active curcumin capsules
Study: NCT03958240

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples, tumor biopsy specimens and ascites samples will be collected.
Description: Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice) for a maximum follow-up period of 5 years from baseline:~* at Baseline.~* at every surgical procedure or tumor biopsy.~* every 6 months (± 2 months) (only blood sample).~* at the time of the progression or recurrence, additional samples will be collected, and optionally at the time of the following progressions or recurrences (if applicable).~For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks).
Study: NCT04515667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will view a brief mindfulness video

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video
Description: Participants will view a control video
Study: NCT01080651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
Study: NCT03444935

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Follow-up phone call
Description: Please see arm/group description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up phone call
Description: Please see arm/group description.
Study: NCT03929926

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: receive usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Educational Materials
Description: Receive educational materials via mail

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Educational Materials
Description: Receive educational materials via mail

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive shared decision making and lung cancer screening information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive shared decision making and lung cancer screening information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo decision counseling session
Study: NCT01493960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobitolimod
Description: 30 mg rectal dose at week 0 and 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal dose at week 0 and 4
Study: NCT02215330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT00345813

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein isolate
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT00602186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsolusin
Description: 0.4 mg /day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin
Description: 1 mg/day
Study: NCT01266447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT00674115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/sodium bicarbonate
Description: Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole magnesium
Description: Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: Sodium bicarbonate. Single dose.
Study: NCT01516203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol, isoniazid, pyrazinamide, rifampin
Description: Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
Study: NCT00380120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium warfarin
Description: dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium warfarin
Description: dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium warfarin
Description: As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium warfarin
Description: As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
Study: NCT02208570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV>14%
Description: Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV>14%
Description: Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volume loading
Description: Hydroxyethyl starch solution 6ml/kg iv injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volume loading
Description: Hydroxyethyl starch solution 6ml/kg iv injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV<14%
Description: Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV<14%
Description: Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
Study: NCT02783820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match MMV390048 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match MMV390048 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 120 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match MMV390048 120 mg
Study: NCT00201864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg orally per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 mg IM starting on Day 8 and then every 28 days.
Study: NCT02020499

Intervention type: DRUG
Intervention: Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
Description: Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
Study: NCT04610216

Intervention type: DEVICE
Intervention: Naida CI M hearing device
Description: speech intelligibility measurement with Naida CI M hearing device

Intervention type: DEVICE
Intervention: Naida CI M hearing device
Description: speech intelligibility measurement with Naida CI M hearing device
Study: NCT02890238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene citrate
Description: 50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: 50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: 20mg tab from 7th-11th day of the same cycle orally 3times/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tab from 7th-11th day of the same cycle orally 3times/day
Study: NCT02429687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT01333878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous Abatacept
Description: Subcutaneous Abatacept 125 mg once weekly for 6 months
Study: NCT00956696

Intervention type: DRUG
Intervention: topiramate
Description: oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
Study: NCT04662671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD-X19
Description: Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RD-X19
Description: Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
Study: NCT03739294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol Trifenatate
Description: Asthma inhalation medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol Trifenatate
Description: Asthma inhalation medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol Trifenatate
Description: Asthma inhalation medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol Trifenatate
Description: Asthma inhalation medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol Trifenatate
Description: Asthma inhalation medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol Trifenatate
Description: Asthma inhalation medication
Study: NCT03596281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 400 or 300 mg Q3W IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Description: 15 or 20 or 30 mg/m² Q3W IV